Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BONK, INC.SHOT · Entity 8011 | Director · Former CSO, Chairman | March 01, 2024 | March 06, 2024 |
| Cadrenal Therapeutics, Inc.CVKD · Entity 8251 | Director | October 09, 2026 | October 13, 2026 |
| Caring Brands, Inc.CABR · Entity 7825 | Director · Chief Executive Officer | March 27, 2026 | March 27, 2026 |
| Marker Therapeutics, Inc.TPIV · Entity 7609 | Director | October 09, 2018 | October 10, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BONK, INC.
Report date March 01, 2024 · Filed March 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security | Direct | 187,344 |
Reported balance
After 2024-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-01 · Disposition to issuer · Acquired 1,900,000 · Balance 187,344 F1: The options have an exercise price ranging between $0.84 to $1.30. F2: The options were disposed of, for an aggregate price of $190,000, under an omnibus agreement entered into by and among the Reporting Person, Jarrett Boon, John Gulyus, Brian John, and Safety Shot, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have an exercise price ranging between $0.84 to $1.30.
F2: The options were disposed of, for an aggregate price of $190,000, under an omnibus agreement entered into by and among the Reporting Person, Jarrett Boon, John Gulyus, Brian John, and Safety Shot, Inc.
Cadrenal Therapeutics, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2036-10-08 | Direct | 75,000 |
Reported balance
After 2026-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.
Caring Brands, Inc.
Report date March 27, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 672,592 |
Reported balance
After 2026-03-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-27 · Disposition to issuer · Disposed 1,500,000 · Balance 672,592 F1: Represents redemption of 1,500,000 shares of common stock of the Issuer at approximately $0.50 per share pursuant to that certain Share Redemption Agreement signed by the Reporting Person and the Issuer on March 19, 2026. F2: The number of shares of common stock beneficially owned following the reported transaction includes Dr. Wilson's ownership of (i) 126,720 restricted stock units of common stock of the Issuer of which zero have vested, (ii) 45,872 restricted stock units of common stock of the Issuer of which zero have vested, and (iii) 500,000 shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents redemption of 1,500,000 shares of common stock of the Issuer at approximately $0.50 per share pursuant to that certain Share Redemption Agreement signed by the Reporting Person and the Issuer on March 19, 2026.
F2: The number of shares of common stock beneficially owned following the reported transaction includes Dr. Wilson's ownership of (i) 126,720 restricted stock units of common stock of the Issuer of which zero have vested, (ii) 45,872 restricted stock units of common stock of the Issuer of which zero have vested, and (iii) 500,000 shares of common stock.
Marker Therapeutics, Inc.
Report date October 09, 2018 · Filed October 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,776 |
Ending reported balance
After 2018-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-10-09 · Grant · Acquired 31,120 · Balance 189,337 F1: Represents issuance of fully vested shares of common stock under the Company's 2014 Omnibus Stock Ownership Plan pursuant to the Company's obligation to do so under the terms of the Reporting Person's employment agreement as amended. Row 2 · 2018-10-09 · Tax withholding · Disposed 7,561 · Balance 181,776 F2: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the stock award. |
| Employee Employment Agreement (right to receive)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-09 · Exercise / conversion · Disposed 31,120 · Balance 0 F3: Represents elimination of Reporting Person's right to receive shares under his employment agreement following the issuance of the shares to the Reporting Person reflected on Table I by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents issuance of fully vested shares of common stock under the Company's 2014 Omnibus Stock Ownership Plan pursuant to the Company's obligation to do so under the terms of the Reporting Person's employment agreement as amended.
F2: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the stock award.
F3: Represents elimination of Reporting Person's right to receive shares under his employment agreement following the issuance of the shares to the Reporting Person reflected on Table I by the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 21:30 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001213900-26-109124 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-10-08 F1 · shares: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. F1 · derivative.exercise_date: The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026. Read SEC document |
| March 27, 2026 Filed Mar 27, 2026 22:56 UTC | Caring Brands, Inc. CABR · Entity 7825 | Disposition to issuerCommon Stock | 1,500,000 | $0.50 | $750,000.00 |
DisclosureSEC source: 0001493152-26-013341 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,592 F1 · kind: Represents redemption of 1,500,000 shares of common stock of the Issuer at approximately $0.50 per share pursuant to that certain Share Redemption Agreement signed by the Reporting Person and the Issuer on March 19, 2026. F2 · balance_after: The number of shares of common stock beneficially owned following the reported transaction includes Dr. Wilson's ownership of (i) 126,720 restricted stock units of common stock of the Issuer of which zero have vested, (ii) 45,872 restricted stock units of common stock of the Issuer of which zero have vested, and (iii) 500,000 shares of common stock. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 01:51 UTC | Caring Brands, Inc. CABR · Entity 7825 | GrantCommon Stock | 45,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-027838 · ownership.xml · nonDerivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,172,592 F2 · shares: On December 11, 2025, on recommendation of the Compensation Committee of the Board of the Issuer, the Board approved the issuance of 45,872 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on December 11, 2026. The vesting of shares is subject to Dr. Wilson's continued service with the Company. F3 · balance_after: The number of shares of common stock beneficially owned following the reported transactions includes Dr. Wilson's ownership of 2,000,000 shares of common stock. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 01:51 UTC | Caring Brands, Inc. CABR · Entity 7825 | GrantCommon Stock | 126,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-027838 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,126,720 F1 · shares: On December 11, 2025, on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Issuer, the Board approved the issuance of 126,720 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on June 11, 2026. The vesting of shares is subject to Dr. Wilson's continued services with the Company. F3 · balance_after: The number of shares of common stock beneficially owned following the reported transactions includes Dr. Wilson's ownership of 2,000,000 shares of common stock. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 18:13 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006639 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-22 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 17:20 UTC | BONK, INC. SHOT · Entity 8011 | Disposition to issuerStock Options · Derivative | 1,900,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-009074 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · Former CSO, Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,344 Underlying: Common Stock · 1,900,000 shares Expires not disclosed F1 · derivative.exercise_price: The options have an exercise price ranging between $0.84 to $1.30. F2 · price: The options were disposed of, for an aggregate price of $190,000, under an omnibus agreement entered into by and among the Reporting Person, Jarrett Boon, John Gulyus, Brian John, and Safety Shot, Inc. F2 · derivative.expiration_date: The options were disposed of, for an aggregate price of $190,000, under an omnibus agreement entered into by and among the Reporting Person, Jarrett Boon, John Gulyus, Brian John, and Safety Shot, Inc. F2 · balance_after: The options were disposed of, for an aggregate price of $190,000, under an omnibus agreement entered into by and among the Reporting Person, Jarrett Boon, John Gulyus, Brian John, and Safety Shot, Inc. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 19:38 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 70,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-004996 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-01-17 F1 · security: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 17:02 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | ConversionConvertible Promissory Note · Derivative | 50,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-004886 · ownership.xml · derivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. F1 · derivative.exercise_date: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. F1 · derivative.expiration_date: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 17:02 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | ConversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-004886 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share. Read SEC document |
| December 30, 2022 Filed Dec 30, 2022 18:15 UTC | BONK, INC. JUPW · Entity 8011 | GrantStock Options · Derivative | 1,050,000 | Not disclosed Strike: $0.76 | Not disclosed |
DisclosureSEC source: 0001493152-22-037199 · ownership.xml · derivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,236,194 Underlying: Common Stock · 1,050,000 shares Expires not disclosed F1 · price: The options are granted under the 2022 Equity Incentive plans, with an exercise price of $0.7600 based on the closing sale price of Company's common stock on December 29, 2022. The options are exercisable within five years from the transaction date herein. F1 · derivative.expiration_date: The options are granted under the 2022 Equity Incentive plans, with an exercise price of $0.7600 based on the closing sale price of Company's common stock on December 29, 2022. The options are exercisable within five years from the transaction date herein. F1 · balance_after: The options are granted under the 2022 Equity Incentive plans, with an exercise price of $0.7600 based on the closing sale price of Company's common stock on December 29, 2022. The options are exercisable within five years from the transaction date herein. Read SEC document |
| July 26, 2022 Filed Jul 27, 2022 20:42 UTC | BONK, INC. JUPW · Entity 8011 | Disposition to issuerStock Options · Derivative | 2,750 | Not disclosed Strike: $1.77 | Not disclosed |
DisclosureSEC source: 0001493152-22-020452 · ownership.xml · derivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,186,194 Underlying: Common Stock · 2,750 shares Expires not disclosed F1 · price: On July 26, 2021 the Reporting Person surrendered 2,750 options to purchases Issuer's common stock and now owns 155,444 options to purchases Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. On July 26, 2021 the Reporting Person surrendered 14,124 shares of common stock issued to him pursuant to the Issuer's 2021 Equity Incentive Plan. F1 · derivative.exercise_date: On July 26, 2021 the Reporting Person surrendered 2,750 options to purchases Issuer's common stock and now owns 155,444 options to purchases Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. On July 26, 2021 the Reporting Person surrendered 14,124 shares of common stock issued to him pursuant to the Issuer's 2021 Equity Incentive Plan. F1 · derivative.expiration_date: On July 26, 2021 the Reporting Person surrendered 2,750 options to purchases Issuer's common stock and now owns 155,444 options to purchases Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. On July 26, 2021 the Reporting Person surrendered 14,124 shares of common stock issued to him pursuant to the Issuer's 2021 Equity Incentive Plan. F1 · balance_after: On July 26, 2021 the Reporting Person surrendered 2,750 options to purchases Issuer's common stock and now owns 155,444 options to purchases Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. On July 26, 2021 the Reporting Person surrendered 14,124 shares of common stock issued to him pursuant to the Issuer's 2021 Equity Incentive Plan. Read SEC document |
| July 26, 2022 Filed Jul 27, 2022 20:42 UTC | BONK, INC. JUPW · Entity 8011 | Disposition to issuerCommon Stock | 14,124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-020452 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 F1 · shares: On July 26, 2021 the Reporting Person surrendered 2,750 options to purchases Issuer's common stock and now owns 155,444 options to purchases Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. On July 26, 2021 the Reporting Person surrendered 14,124 shares of common stock issued to him pursuant to the Issuer's 2021 Equity Incentive Plan. F1 · price: On July 26, 2021 the Reporting Person surrendered 2,750 options to purchases Issuer's common stock and now owns 155,444 options to purchases Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. On July 26, 2021 the Reporting Person surrendered 14,124 shares of common stock issued to him pursuant to the Issuer's 2021 Equity Incentive Plan. F1 · balance_after: On July 26, 2021 the Reporting Person surrendered 2,750 options to purchases Issuer's common stock and now owns 155,444 options to purchases Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. On July 26, 2021 the Reporting Person surrendered 14,124 shares of common stock issued to him pursuant to the Issuer's 2021 Equity Incentive Plan. Read SEC document |
| July 26, 2022 Filed Dec 30, 2022 18:15 UTC | BONK, INC. JUPW · Entity 8011 | Disposition to issuerCommon Stock | 14,124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-037199 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 F1 · shares: The options are granted under the 2022 Equity Incentive plans, with an exercise price of $0.7600 based on the closing sale price of Company's common stock on December 29, 2022. The options are exercisable within five years from the transaction date herein. F1 · price: The options are granted under the 2022 Equity Incentive plans, with an exercise price of $0.7600 based on the closing sale price of Company's common stock on December 29, 2022. The options are exercisable within five years from the transaction date herein. F1 · balance_after: The options are granted under the 2022 Equity Incentive plans, with an exercise price of $0.7600 based on the closing sale price of Company's common stock on December 29, 2022. The options are exercisable within five years from the transaction date herein. Read SEC document |
| December 06, 2021 Filed Jan 27, 2022 21:36 UTC | BONK, INC. JUPW · Entity 8011 | GrantStock Options · Derivative | 25,000 | Not disclosed Strike: $1.41 | Not disclosed |
DisclosureSEC source: 0001493152-22-002457 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-05 F1 · derivative.exercise_price: On December 6, 2021, and pursuant to the Issuer's 2021 Incentive Equity Plan, the Reporting Person received options to purchase up to 25,000 shares of the Issuer's common stock, par value $0.001 (the "Options"), at an exercise price of $1.41. The Options are exercisable for a period of five years and vested immediately. F1 · price: On December 6, 2021, and pursuant to the Issuer's 2021 Incentive Equity Plan, the Reporting Person received options to purchase up to 25,000 shares of the Issuer's common stock, par value $0.001 (the "Options"), at an exercise price of $1.41. The Options are exercisable for a period of five years and vested immediately. F2 · balance_after: On November 24, 2021 pursuant to a board resolution the Reporting Person was awarded 1,000,000 options to purchase Issuer's common stock, pursuant to the Issuer's 2021 Equity Incentive Plan. On December 6, 2021, the Reporting Person surrendered 100,000 options and now owns 900,000 options to purchases Issuer's common stock, at an exercise price of $1.41. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 16:30 UTC | BONK, INC. JUPW · Entity 8011 | GrantStock Options · Derivative | 875,000 | Not disclosed Strike: $1.41 | Not disclosed |
DisclosureSEC source: 0001493152-21-030014 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Underlying: Common Stock · 875,000 shares Expires 2026-11-24 F1 · derivative.exercise_price: On November 24, 2021, and pursuant to the Issuer's 2021 Incentive Equity Plan, the Reporting Person received options to purchase up to 875,000 shares of the Issuer's common stock, par value $0.001 (the "Options"), at an exercise price of $1.41. The exercise price of the Options was based on the closing price of the Issuer's common stock on the day prior to the grant. The Options are exercisable for a period of five years and vested immediately. F1 · price: On November 24, 2021, and pursuant to the Issuer's 2021 Incentive Equity Plan, the Reporting Person received options to purchase up to 875,000 shares of the Issuer's common stock, par value $0.001 (the "Options"), at an exercise price of $1.41. The exercise price of the Options was based on the closing price of the Issuer's common stock on the day prior to the grant. The Options are exercisable for a period of five years and vested immediately. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 16:30 UTC | BONK, INC. JUPW · Entity 8011 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-028643 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 956,024 F1 · date: The shares of common stock were awarded pursuant to the Reporting Peron's Employment Agreement with the Issuer. F1 · kind: The shares of common stock were awarded pursuant to the Reporting Peron's Employment Agreement with the Issuer. F1 · shares: The shares of common stock were awarded pursuant to the Reporting Peron's Employment Agreement with the Issuer. F1 · price: The shares of common stock were awarded pursuant to the Reporting Peron's Employment Agreement with the Issuer. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 19:17 UTC | BONK, INC. JUPW · Entity 8011 | GrantStock Option · Derivative | 155,444 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001493152-21-020610 · ownership.xml · derivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,468 Underlying: Common Stock · 155,444 shares Expires 2026-08-16 F2 · date: The options were issued pursuant to a board resolution dated August 16, 2021 under the 2020 Incentive Equity Plan. F2 · kind: The options were issued pursuant to a board resolution dated August 16, 2021 under the 2020 Incentive Equity Plan. F2 · shares: The options were issued pursuant to a board resolution dated August 16, 2021 under the 2020 Incentive Equity Plan. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 19:17 UTC | BONK, INC. JUPW · Entity 8011 | GrantCommon Stock | 14,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-020610 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · CSO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,024 F1 · date: The shares of common stock were awarded pursuant to a board resolution dated August 16, 2021 and the 2020 Incentive Equity Plan as a form of compensation. F1 · kind: The shares of common stock were awarded pursuant to a board resolution dated August 16, 2021 and the 2020 Incentive Equity Plan as a form of compensation. F1 · shares: The shares of common stock were awarded pursuant to a board resolution dated August 16, 2021 and the 2020 Incentive Equity Plan as a form of compensation. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 19:56 UTC | BONK, INC. JUPW · Entity 8011 | SaleCommon Stock | 50,000 | $2.79 | $139,500.00 |
DisclosureSEC source: 0001493152-21-017896 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 F1 · date: The shares of common stock were sold pursuant to the Company's underwritten public offering under a registration statement (File Number: 333-258005) filed with the Securities Exchange Commission which became effective on July 21, 2021. The holder paid a fee of $0.23 per share in underwriting fees. F1 · kind: The shares of common stock were sold pursuant to the Company's underwritten public offering under a registration statement (File Number: 333-258005) filed with the Securities Exchange Commission which became effective on July 21, 2021. The holder paid a fee of $0.23 per share in underwriting fees. F1 · shares: The shares of common stock were sold pursuant to the Company's underwritten public offering under a registration statement (File Number: 333-258005) filed with the Securities Exchange Commission which became effective on July 21, 2021. The holder paid a fee of $0.23 per share in underwriting fees. F1 · price: The shares of common stock were sold pursuant to the Company's underwritten public offering under a registration statement (File Number: 333-258005) filed with the Securities Exchange Commission which became effective on July 21, 2021. The holder paid a fee of $0.23 per share in underwriting fees. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:23 UTC | BONK, INC. JUPW · Entity 8011 | GrantOption · Derivative | 33,500 | Not disclosed Strike: $4.48 | Not disclosed |
DisclosureSEC source: 0001264931-21-000093 · ownership.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · Not disclosed shares Expires 2026-06-30 F1 · price: Derivative securities issued pursuant to company's equity incentive plan. F1 · derivative.underlying_shares: Derivative securities issued pursuant to company's equity incentive plan. Read SEC document |
| December 14, 2020 Filed Dec 31, 2020 16:59 UTC | BONK, INC. JUPW · Entity 8011 | ConversionCommon Stock | 200,000 | $0.25 | $50,000.00 |
DisclosureSEC source: 0001264931-20-000263 · ownership.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The 200,000 shares of common stock were issued to Mr. Wilson pursuant to the conversion of a promissory note, dated July 25, 2019. F2 · balance_after: Includes 300,000 shares of common stock authorized by the board of directors of Jupiter Wellness, Inc. but not yet issued to Mr. Wilson. Read SEC document |
| October 09, 2018 Filed Oct 10, 2018 20:50 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | Exercise / conversionEmployee Employment Agreement (right to receive) · Derivative | 31,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-053247 · tv504612_4.xml · derivative · entry 3 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents elimination of Reporting Person's right to receive shares under his employment agreement following the issuance of the shares to the Reporting Person reflected on Table I by the Company. F3 · derivative.exercise_date: Represents elimination of Reporting Person's right to receive shares under his employment agreement following the issuance of the shares to the Reporting Person reflected on Table I by the Company. F3 · derivative.expiration_date: Represents elimination of Reporting Person's right to receive shares under his employment agreement following the issuance of the shares to the Reporting Person reflected on Table I by the Company. Read SEC document |
| October 09, 2018 Filed Oct 10, 2018 20:50 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | Tax withholdingCommon Stock | 7,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-053247 · tv504612_4.xml · nonDerivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,776 F2 · shares: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the stock award. Read SEC document |
| October 09, 2018 Filed Oct 10, 2018 20:50 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 31,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-053247 · tv504612_4.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,337 F1 · shares: Represents issuance of fully vested shares of common stock under the Company's 2014 Omnibus Stock Ownership Plan pursuant to the Company's obligation to do so under the terms of the Reporting Person's employment agreement as amended. Read SEC document |
| September 22, 2018 Filed Sep 25, 2018 21:03 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock · Derivative | 31,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-050737 · tv503493_4.xml · derivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,120 Underlying: Common Stock · 31,120 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares of restricted stock the reporting person has a present right to receive under the terms of the amendment to his employment agreement with the Company, and such shares are based on a value of $300,000 and the closing price of the Company's common stock on September 21, 2018 of $9.64 per share, (which was the date immediately preceding the anniversary of the amendment) and upon issuance under the Company's 2014 Omnibus Stock Ownership Plan to be fully vested. F1 · price: Represents the number of shares of restricted stock the reporting person has a present right to receive under the terms of the amendment to his employment agreement with the Company, and such shares are based on a value of $300,000 and the closing price of the Company's common stock on September 21, 2018 of $9.64 per share, (which was the date immediately preceding the anniversary of the amendment) and upon issuance under the Company's 2014 Omnibus Stock Ownership Plan to be fully vested. F1 · derivative.exercise_date: Represents the number of shares of restricted stock the reporting person has a present right to receive under the terms of the amendment to his employment agreement with the Company, and such shares are based on a value of $300,000 and the closing price of the Company's common stock on September 21, 2018 of $9.64 per share, (which was the date immediately preceding the anniversary of the amendment) and upon issuance under the Company's 2014 Omnibus Stock Ownership Plan to be fully vested. F1 · derivative.expiration_date: Represents the number of shares of restricted stock the reporting person has a present right to receive under the terms of the amendment to his employment agreement with the Company, and such shares are based on a value of $300,000 and the closing price of the Company's common stock on September 21, 2018 of $9.64 per share, (which was the date immediately preceding the anniversary of the amendment) and upon issuance under the Company's 2014 Omnibus Stock Ownership Plan to be fully vested. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 20:05 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | Tax withholdingCommon Stock | 27,350 | $3.18 | $86,973.00 |
DisclosureSEC source: 0001144204-17-049725 · v475881_4.xml · nonDerivative · entry 2 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,217 F2 · shares: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the restricted stock award. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 20:05 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 100,000 | $3.18 | $318,000.00 |
DisclosureSEC source: 0001144204-17-049725 · v475881_4.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,567 F1 · shares: Represents shares of fully vested restricted stock issued under the Company's 2014 Omnibus Stock Ownership Plan in connection with the execution of amendment to employment agreement reflecting change in status from President and Chief Executive Officer to Strategic Advisor. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 20:02 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 12,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-014235 · v461697_4.xml · nonDerivative · entry 1 WILSON GLYNN · CIK 0001405625 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,567 F1 · shares: Represents the portion of a discretionary bonus award for 2016 payable as a restricted, immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan. The issuance of 12,761 shares of restricted common stock was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.